China Coronary Secondary Prevention Study
Epidemiologic studies have shown a close relationship between coronary heart disease (CHD) risk and both total (TC) and low-density lipoprotein (LDL-C) serum cholesterol levels. evaluated the treatment effects on measured
lipid levels as well as the safety of Xuezhikang. Patients who were eligible for this study were randomly assigned to receive either Xuezhikang Several large international clinical trials have demonstrated that decreases in the serum TC and LDL-C in western patients with coronary heart disease can reduce recurrent coronary events [1-3]. There are no such studies in Chinese or other east Asian populations. East Asians, especially Chinese, have a lower TC and LDL-C level, but a higher TG and HDL-C level compared with western populations. Moreover, Chinese diet, life style and genetics differ significantly from those of western people. Chinese food has low saturated fatty acid and cholesterol content and Chinese are believed to lead more physically active lives. However, Xuezhikang capsules [4] are a traditional Chinese medicine and lipid-regulating drug which contains extracts from red koji.. This study found that Xuezhikang was safe and effective in the secondary prevention of CHD in China.
Materials and methods
Study Design.
The study was a multi-centre, randomized, double blind and placebo controlled clinical trial. 66 centers (65 medical center and 1 quality control center) in 19 cities and provinces participated in this study. The primary main objective was to investigate whether cholesterol lowering with Xuezhikang capsules would reduce recurrent nonfatal myocardial infarction (MI) and fatal CHD events. Fatal CHD events included fatal MI, sudden death and other
coronary death. The secondary end point included all-cause deaths. Other events recorded and analyzed included malignancies, stroke, need for percutaneous coronary intervention (PCI)/coronary artery bypass grafting (CABG), and all-cause
hospitalization. The study also capsule, 0.6g twice per day (Beijing WBL Peking University Biotech Co., Ltd) or matching placebo. The study prohibited the use of other medications which influence blood lipid level. Previous treatment for CHD, hypertension or complications of CHD was continued. Patients were followed up at 6-8 weeks after randomization and every 6 month thereafter. At each visit, the procedures included comprehensive counseling and determination of serum lipid level and safety parameters. During the follow-up, the dates of all coronary events were recorded. We also recorded the dates of other events including stroke or other cerebro-vascular events, the need for PCI and/or CABG, cancer, accidental death, suicide, other cause death and all-cause hospitalization. Safety.
Patients were asked to continue study medications and follow up unless adverse events were intolerable. The study team recorded adverse events including symptoms and lab abnormalities. Local research center team leaders discontinued study treatment and reported all adverse events to the principal investigators at the lead medical center. Severe or fatal adverse events were reported within 24 hours. A data safety monitoring board, blinded to the assignment of the patients, evaluated clinical end-points and adverse events regularly Inclusion criteria
We recruited men or women with previous history of acute MI occurring between 28 days and 5 years prior to enrollment. Exclusion criteria are listed in Table 1.
A referral laboratory assessed serum lipid levels. Patients who had a TC level between 4.40 mmol/L and 6.47 mmol/L (170-250mg/dl)
and TG level ≤4.52 mmol/L (400mg/dl) were given a bottle of placebo (35 capsules) for
China Coronary Secondary Prevention Study (CCSPS) - Lipid-regulating_英语学习_外语学习_教育专区 暂无评价 0人阅读 0次下载 举报文档 China Coronary ...
Feasibility Study of W... 18页 免费 China Coronary Seconda... 暂无评价...After secondary polymer flooding, just as shown in Table 3, fractional flow...
(二)冠心病二级预防研究 1.中国冠心病二级预防研究(China Coronary Secondary Prevention Study, CCSPS)[26-27] 目前这是我国惟一一项对冠心病二级预防的大规模,前瞻...
9. 中国冠心病二级预防研究(China coronary secondary prevention study,CCSPS): 研究表明老年患者、合并糖尿病或高血压的患者治疗后获益更显著。 特殊人群的降脂临床...
我国从1996年至2000年进 行的中国冠心病二级预防研究(China Coronary Secondary Prevention Study CCSPS)是针对中国冠心病患者进行的冠心病二级预防试验, 是一项为多...
Chapter 6 Secondary synt... 暂无评价 37页 免费 Spoofing Prevention Meth... 暂无评价 18页 免费 China Coronary Secondary... 暂无评价 11页 免费...
血脂与冠心病 ——来自中国循证医学的证据解放军总医院 叶平 CCSPS 中国冠心病二级预防研究 China Coronary Secondary Prevention Study (CCSPS) --血脂康调整血脂对...
coronary heart disease.4 In the past 20 years,...“primary prevention”, “secondary prevention”, ...study in China and it showed the lowest average...
血脂康调整血脂 对冠心病二级预防的研究 China Coronary Secondary Prevention Study (CCSPS) CCSPS) 国家九五攻关课题编号:96-906-02国家九五攻关课题编号:96-906-...
中国冠心病二级预防研究 China Coronary Secondary Prevention Study 中国老年冠心病人群唯一循证医学研究(国家九五攻关课题) 课题牵头单位:阜外心血管病医院课题协作单位:...
热门文档